Study Title

Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX

Study Details

Description:

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Sponsor:

Telix Pharmaceuticals

Contacts:

Kavita Vadali

global-clinicaltrials@telixpharma.com

+61 3 9093 3808

Government Study Link:

NCT05563272 - Click here to see study on

ClinicalTrials.gov

Inclusion

Histologically or cytologically proven solid tumors
Male or female >= 18 years old
At least one non-CNS, measurable target lesion per RECIST 1.1 documented at conventional imaging within 30 days prior

Exclusion

Previous administration of any radionuclide within 10 half-lives prior to administration of 89Zr-girentuximab
Exposure to any antineoplastic treatment within 14 days from planned administration
Exposure to any CAIX-targeting compound in the last 3 months

Patient Education

Patient Education Not Yet Provided

Publications

Abstract from ASCO-GU 2023

Locations

United States

University Hospitals Of Cleveland

Cleveland, Ohio 44106, United States

Austin Radiological Association

Texas, United States

Carilion Clinic

Virginia, United States

Inland Imaging

Washington, United States

Biogenix Molecular LLC

Miami, Florida 33165, United States